Stay updated on MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial
Sign up to get notified when there's something new on the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page.

Latest updates to the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page
- ChecktodayChange DetectedThe record now presents details of the completed MEDI0680 clinical trial, including its study design, eligibility criteria, locations, outcomes, investigators, and results. It also includes study documents and information about requesting access to participant-level data.SummaryDifference100%

- Check7 days agoChange DetectedThe footer now shows site revision v3.8.0 instead of v3.7.2, while the study record remains inaccessible with a 403 Forbidden error.SummaryDifference0.2%

- Check14 days agoChange DetectedA banner appears above the page announcing NIH website updates and linking to transition FAQs. It says NIH content may use “Super Intelligence” alongside “Artificial Intelligence” during the transition.SummaryDifference1%

- Check21 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.2 while the page continued to display a 403 error.SummaryDifference0.2%

- Check49 days agoChange DetectedA 403 Forbidden page now appears when attempting to view the study record, blocking access to the study details and related navigation.SummaryDifference22%

- Check70 days agoChange DetectedA new revision tag, v3.6.6, was added and the previous tag, v3.6.5, was removed. This reflects an update to the site's release information rather than content changes on the page.SummaryDifference0.0%

Stay in the know with updates to MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page.